Multivariate analyses of neutrophil engraftment (ANC ≥ 0.5 × 109/L), platelet engraftment (platelets > 50 × 109/L), aGVHD, and cGVHD
| Variable . | n . | RR (95% Confidence interval) . | P . |
|---|---|---|---|
| Neutrophil engraftment* | |||
| 0.7-2.4 × 107/kg | 233 | 0.7 (0.6-0.8) | < .001¶ |
| 2.5-4.9 × 107/kg | 383 | Reference | |
| 5.0-9.9 × 107/kg | 262 | 1.2 (1.0-1.5) | .026¶ |
| >10.0 × 107/kg | 126 | 1.8 (1.4-2.2) | < .001¶ |
| 0-MM | 53 | 1.8 (1.3-2.5) | < .001¶ |
| 1-MM | 331 | Reference | |
| 2-MM | 556 | 1.0 (0.9-1.2) | .896 |
| 3-MM | 64 | 0.8 (0.6-1.1) | .162 |
| Platelet engraftment* | |||
| 0.7-2.4 × 107/kg | 226 | 0.7 (0.5-0.9) | .006¶ |
| 2.5-4.9 × 107/kg | 358 | Reference | |
| 5.0-9.9 × 107/kg | 256 | 1.4 (1.1-1.7) | .008¶ |
| More than 10.0 × 107/kg | 123 | 1.8 (1.4-2.4) | < .001¶ |
| 0-MM | 49 | 1.8 (1.2-2.5) | .002¶ |
| 1-MM | 316 | Reference | |
| 2-MM | 534 | 0.8 (0.6-0.9) | .027¶ |
| 3-MM | 64 | 0.5 (0.3-0.8) | .006¶ |
| Grade 3-4 aGVHD†‡ | |||
| 0-MM | 43 | 0.3 (0.1-0.9) | .030¶ |
| 1-MM | 229 | Reference | |
| 2-MM | 382 | 1.4 (1.0-2.0) | .039¶ |
| 3-MM | 41 | 1.8 (1.0-3.3) | .050¶ |
| cGVHD§‖ | |||
| 0-MM | 30 | 0.9 (0.4-1.8) | .781 |
| 1-MM | 150 | Reference | |
| 2-MM | 213 | 1.3 (0.9-1.9) | .184 |
| 3-MM | 19 | 2.4 (1.2-4.6) | .011¶ |
| Variable . | n . | RR (95% Confidence interval) . | P . |
|---|---|---|---|
| Neutrophil engraftment* | |||
| 0.7-2.4 × 107/kg | 233 | 0.7 (0.6-0.8) | < .001¶ |
| 2.5-4.9 × 107/kg | 383 | Reference | |
| 5.0-9.9 × 107/kg | 262 | 1.2 (1.0-1.5) | .026¶ |
| >10.0 × 107/kg | 126 | 1.8 (1.4-2.2) | < .001¶ |
| 0-MM | 53 | 1.8 (1.3-2.5) | < .001¶ |
| 1-MM | 331 | Reference | |
| 2-MM | 556 | 1.0 (0.9-1.2) | .896 |
| 3-MM | 64 | 0.8 (0.6-1.1) | .162 |
| Platelet engraftment* | |||
| 0.7-2.4 × 107/kg | 226 | 0.7 (0.5-0.9) | .006¶ |
| 2.5-4.9 × 107/kg | 358 | Reference | |
| 5.0-9.9 × 107/kg | 256 | 1.4 (1.1-1.7) | .008¶ |
| More than 10.0 × 107/kg | 123 | 1.8 (1.4-2.4) | < .001¶ |
| 0-MM | 49 | 1.8 (1.2-2.5) | .002¶ |
| 1-MM | 316 | Reference | |
| 2-MM | 534 | 0.8 (0.6-0.9) | .027¶ |
| 3-MM | 64 | 0.5 (0.3-0.8) | .006¶ |
| Grade 3-4 aGVHD†‡ | |||
| 0-MM | 43 | 0.3 (0.1-0.9) | .030¶ |
| 1-MM | 229 | Reference | |
| 2-MM | 382 | 1.4 (1.0-2.0) | .039¶ |
| 3-MM | 41 | 1.8 (1.0-3.3) | .050¶ |
| cGVHD§‖ | |||
| 0-MM | 30 | 0.9 (0.4-1.8) | .781 |
| 1-MM | 150 | Reference | |
| 2-MM | 213 | 1.3 (0.9-1.9) | .184 |
| 3-MM | 19 | 2.4 (1.2-4.6) | .011¶ |
aGVHD indicates acute graft-versus-host disease; ANC, absolute neutrophil count; CBT, cord blood transplant; cGVHD, chronic graft-versus-host disease; CSA, cyclosporine-A; JCML, juvenile chronic myeloid leukemia; MM, mismatch; RR, relative risk; TNC, total nucleated cells; TRM, transplant-related mortality; and US, United States.
Other predictive variables, such as more recent year of transplantation (2003-2006) and transplantation in more-experienced US centers, were associated with improved neutrophil and platelet engraftment. GVHD prophylaxis with methotrexate (compared with CSA and corticosteroids) was associated with an inferior engraftment rate.
Other predictive variables, such as GVHD prophylaxis with methotrexate (compared with CSA and corticosteroids), were associated with less aGVHD, whereas older patient age and transplantation in less-experienced US centers were associated with a greater incidence of severe aGVHD. TNC dose and patient ethnicity had no association with aGVHD.
Analysis was performed among patients who engrafted according to transplant center assignment. Reanalysis of severe acute GVHD according to International Bone Marrow Transplant Registry grade with reported organ involvement yielded similar results (data not shown).
Other predictive variables, such as older patient age, nonwhite ancestry, and transplantation in less experienced US centers, were associated with a greater risk of cGVHD. TNC dose and GVHD prophylaxis had no association with cGVHD.
Analysis was performed among patients who engrafted and survived ≥ 100 days after transplant.
Statistically significant P value.